https://www.fool.com/investing/general/2011/07/19/hong-kong-forces-second-gsk-recall.aspx
https://www.fool.com/investing/general/2011/06/29/musty-smell-touches-off-yet-another-jj-recall.aspx
https://www.fool.com/investing/general/2010/10/18/sanofi-will-attend-harvard-in-hunt-for-new-blockbu.aspx
https://www.fool.com/investing/general/2011/07/12/gilead-first-to-jump-into-aids-patent-pool.aspx
https://www.fool.com/investing/general/2011/11/14/has-amgen-crossed-into-big-pharma-territory.aspx
https://www.fool.com/investing/general/2011/07/08/sanofis-multaq-takes-hit-from-trial-failure.aspx
https://www.fool.com/investing/general/2011/07/08/pfizer-move-disappoints-break-up-champions.aspx
https://www.fool.com/investing/general/2011/07/08/lilly-chief-scolds-germany-for-new-pharma-rules.aspx
https://www.fool.com/investing/general/2011/09/23/europe-calls-for-limits-on-sanofis-multaq.aspx
